RC
LSTA icon

Rangeley Capital’s Lisata Therapeutics LSTA Stock Holding History

Rangeley Capital’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$275K Buy
81,000
+6,000
+8% +$21.4K 0.25% 96
2026
Q1 		$376K Buy
+75,000
New +$310K 0.37% 60

Other funds holding LSTA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rangeley Capital's LSTA Position: Q2 2026 in Review

Rangeley Capital increased its Lisata Therapeutics (LSTA) stake by 8% in Q2 2026, buying an estimated $21.4K and bringing the position to 81,000 shares worth $275K. The position accounts for 0.25% of the portfolio, ranked #96.

Rangeley Capital first reported a position in LSTA in Q1 2026 and has held it in 2 quarters since. The position peaked at $376K in Q1 2026. 31 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.

  • Rangeley Capital held 81,000 shares of Lisata Therapeutics worth $275K as of Q2 2026.
  • Rangeley Capital bought 6,000 Lisata Therapeutics shares in Q2 2026, an estimated $21.4K.
  • Lisata Therapeutics made up 0.25% of Rangeley Capital's portfolio in Q2 2026, its #96 holding.
  • Rangeley Capital first reported a position in Lisata Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Rangeley Capital's Lisata Therapeutics position peaked at $376K in Q1 2026.
  • 31 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.